These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37524153)

  • 1. Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: Consensus report from the Registry Assessment of Peripheral Interventional Devices (RAPID) Pathways "LEAN" working group.
    Black JH; Buckley D; Velezis M; Eldrup-Jorgensen J; Serratore ND; Gutierrez JA; Whatley E; Marmor RA; Bertges DJ; Tcheng JE; Royce S; Malone M; Farb A; Secemsky EA; Parikh SA; Smale J; Jaff MR; White R; Wilgus RW; Krucoff MW
    J Vasc Surg; 2023 Nov; 78(5):1313-1321. PubMed ID: 37524153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality in patients undergoing revascularization with paclitaxel eluting devices for infrainguinal peripheral artery disease: Insights from a network meta-analysis of randomized trials.
    Kuno T; Ueyama H; Mikami T; Takagi H; Numasawa Y; Anzai H; Bangalore S
    Catheter Cardiovasc Interv; 2020 Oct; 96(4):E467-E478. PubMed ID: 32691953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased mortality with paclitaxel-eluting stents is driven by lesion length.
    Mathlouthi A; Yei KS; Naazie I; Bertges DJ; Malas MB
    J Vasc Surg; 2021 Feb; 73(2):548-553.e2. PubMed ID: 32615286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease.
    Kim TI; Kiwan G; Mohamedali A; Zhang Y; Mena-Hurtado C; Mojibian H; Guzman RJ; Ochoa Chaar CI
    J Vasc Surg; 2021 Mar; 73(3):911-917. PubMed ID: 33038480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endovascular community response to mortality data in use of paclitaxel devices for peripheral vascular disease.
    Warren BE; Roche-Nagle G; Zhu J; Wang G; Eisenberg N; Rajan DK; Mafeld S
    J Vasc Surg; 2021 Dec; 74(6):2006-2013.e2. PubMed ID: 34182026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements.
    Jones WS; Krucoff MW; Morales P; Wilgus RW; Heath AH; Williams MF; Tcheng JE; Marinac-Dabic JD; Malone ML; Reed TL; Fukaya R; Lookstein RA; Handa N; Aronow HD; Bertges DJ; Jaff MR; Tsai TT; Smale JA; Zaugg MJ; Thatcher RJ; Cronenwett JL
    J Vasc Surg; 2018 Feb; 67(2):637-644.e30. PubMed ID: 29389426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Femoral-popliteal peripheral artery disease: From symptom presentation to management and treatment controversies.
    Krawisz AK; Raja A; Secemsky EA
    Prog Cardiovasc Dis; 2021; 65():15-22. PubMed ID: 33592208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions.
    Katsuki T; Takahara M; Soga Y; Okamoto S; Iida O; Fujihara M; Kawasaki D; Ando K
    J Endovasc Ther; 2019 Oct; 26(5):593-599. PubMed ID: 31431154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single-Center Experience of Paclitaxel in the Treatment of Femoropopliteal Disease-No Evidence for an Association With Mortality.
    Linehan V; Doyle M; Barrett B; Gullipalli R
    Vasc Endovascular Surg; 2020 Jul; 54(5):400-405. PubMed ID: 32319355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Term Outcomes After Revascularisations Below the Knee with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
    Heidemann F; Peters F; Kuchenbecker J; Kreutzburg T; Sedrakyan A; Marschall U; L'Hoest H; Debus ES; Behrendt CA
    Eur J Vasc Endovasc Surg; 2020 Oct; 60(4):549-558. PubMed ID: 32807674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel exposure and long-term mortality of patients treated with the Zilver PTX drug-eluting stent.
    Stern JR; Tran K; Chandra V; Harris EJ; Lee JT
    Vascular; 2021 Aug; 29(4):567-573. PubMed ID: 33054678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status of drug-coated devices in lower extremity peripheral artery disease interventions.
    Amlani V; Falkenberg M; Nordanstig J
    Prog Cardiovasc Dis; 2021; 65():23-28. PubMed ID: 33587964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality After Paclitaxel Coated Balloon Angioplasty and Stenting of Superficial Femoral and Popliteal Artery in the Vascular Quality Initiative.
    Bertges DJ; Sedrakyan A; Sun T; Eslami MH; Schermerhorn M; Goodney PP; Beck AW; Cronenwett JL; Eldrup-Jorgensen J
    Circ Cardiovasc Interv; 2020 Feb; 13(2):e008528. PubMed ID: 32069110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program.
    Lottes AE; Whatley EM; Royce SM; Bertges DJ; Erickson CA; Farb A; Fox ML; Jiang JH; Wang L; Lin AY; Malone ML; Papandreou G; Wilgus RW; Rosenfield K; Krucoff MW
    Am Heart J; 2021 Feb; 232():71-83. PubMed ID: 33157067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of mortality following paclitaxel drug-coated stent angioplasty of femoropopliteal lesions in real world.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Nührenberg T; Cheung F; Neumann FJ; Zeller T
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1306-1314. PubMed ID: 32930497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?
    Gad MM; Karrthik AK; Mahmoud AA; Mahmoud AN
    Curr Cardiol Rep; 2019 Sep; 21(10):126. PubMed ID: 31494770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Dinh K; Gomes ML; Thomas SD; Paravastu SCV; Holden A; Schneider PA; Varcoe RL
    J Endovasc Ther; 2020 Apr; 27(2):175-185. PubMed ID: 32066315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent.
    Golzar J; Soga Y; Babaev A; Iida O; Kawasaki D; Bachinsky W; Park J; Prem JT; Vermassen F; Diaz-Cartelle J; Müller-Hülsbeck S; Gray WA
    J Endovasc Ther; 2020 Apr; 27(2):296-303. PubMed ID: 31989856
    [No Abstract]   [Full Text] [Related]  

  • 19. Strut Coverage After Paclitaxel-Eluting Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Fukunaga M; Nishimura M; Horimatsu T; Saita T; Sumiyoshi A; Tamaru H; Imanaka T; Shibuya M; Naito Y; Masuyama T; Ishihara M
    JACC Cardiovasc Imaging; 2016 Jun; 9(6):753-5. PubMed ID: 26298069
    [No Abstract]   [Full Text] [Related]  

  • 20. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
    Gouëffic Y; Kaladji A; Guyomarch B; Montagne C; Fairier D; Gestin S; Riche VP; Vent PA; Chaillou P; Costargent A; Patra P
    Trials; 2014 Oct; 15():423. PubMed ID: 25359394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.